Premier Partners

Premier Partners, established in 2005, is a South Korean investment management company headquartered in Seoul. It specializes in venture capital and private equity, focusing on small to mid-sized enterprises within the bio, life science, healthcare, mobility, industrials, and digital sectors. The company offers investment services to both individual and corporate clients, supporting the growth of innovative businesses in South Korea.

Hosung Ahn

Director

Seungmin Baeg

Principal

Joonyoun Cho

Managing Partner

Sung-In Chung

Co-Founder, Co-CEO and Managing Partner

SungIn Chung

Managing Partner / Founder

Jungpyo Hong

Principal, Bio Division

Cheongjo Hwang JD

Principal

Hyeonhwan Jang

Principal

Donghoon Jeon

Managing Partner

Sunjae Jung

Principal

Seong Kim

Managing Partner / CEO

Jinho Kim

Principal, Information Technology

Daniel Kim

Principal

Minbeom Kim

Managing Director

Kyung Kim

Senior Associate

Tae woong Kwon

Partner and Managing Director

Donghoon Lee

Managing Partner

Jason Oh

Principal

David Oh

Partner and Managing Director

Seungmin Roh JD

Principal

BongSoo Shin

Managing Director

Jay Song

CEO

Kim Sung woong

CEO

Hayoung Yun

Director

Hyun-moo Cho

Director and Executive of Bio Division

198 past transactions

Medisolar

Series A in 2025
Medisol is a food technology firm that also provides personalized food care solutions.

Prazer Therapeutics

Series B in 2025
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design methodologies, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By focusing on areas of unmet medical need, Prazer Therapeutics aims to advance drug development and provide solutions for diseases that currently lack effective therapies.

Healing Paper

Series C in 2025
Healing Paper is a company focused on enhancing access to medical beauty services through the use of information and communication technology. It operates a platform that provides estimates and reviews for cosmetic surgeries, aimed at improving the quality of these services. The platform offers users transparent pricing information, authentic reviews, and a community for real-time interaction regarding cosmetic procedures. Additionally, Healing Paper includes a management package for aftercare, ensuring that patients receive comprehensive support throughout their treatment journey. By balancing information between medical professionals and patients, the company strives to make cosmetic treatments more accessible and affordable.

Gangnam Unni

Series C in 2025
Gangnam Unni is in the field of beauty medical services, helping users choose a treatment and a plastic surgery hospital. The difficulty of navigating the process of seeking medical treatment and choosing a hospital continues to persist. Kangnam Unni recognizes the need for change and firmly believes that a combination of transparent medical information and an IT platform can foster a consumer-oriented medical service market. Their ultimate goal is to challenge negative perceptions surrounding plastic surgery and spearhead a significant transformation in the beauty and medical service industries. The Gangnam Unni team is dedicated to innovation, fueled by an unwavering desire to provide exceptional beauty and medical services. With the aim of assisting individuals in selecting a suitable hospital, they have amassed an impressive database of one million user reviews. Additionally, their efforts to promote transparency in medical information have garnered the support of 3,000 subscribers through Gangnam Sister. Furthermore, their mobile application has facilitated hospital consultations for a staggering 3.8 million individuals, resulting in 1.6 million successful cases. As the team continuously clarifies its mission and forges ahead with determination, its collective strength and resolve only grow stronger. Kangnam Unni remains committed to revolutionizing the healthcare industry, ensuring that individuals receive the highest quality of care and a positive experience throughout their medical journeys.

Microbiotix

Series B in 2024
MicrobiotiX is a biotechnology company focused on developing innovative therapeutics that utilize bacteriophages and the microbiome to address multidrug-resistant infections and autoimmune diseases. The company's platform incorporates safe gastrointestinal microbiota transplants and formulates fecal microbiota transplant capsules for oral administration. By researching and developing effective bacteriophage therapies, MicrobiotiX aims to provide convenient and economical treatment options for patients, enhancing the healthcare sector's ability to combat challenging medical conditions.

Aigen Sciences

Series A in 2024
Aigen Sciences is an artificial intelligence-driven drug discovery platform that focuses on the research and development of high-potency pharmaceuticals. The company employs advanced AI technology to discover drugs that effectively induce targeted cellular activity while minimizing off-target effects and toxicity. By streamlining the drug discovery process, Aigen Sciences enables clients to obtain effective medications rapidly and at a reduced cost. Its innovative approach aims to enhance the efficiency and effectiveness of drug development, positioning the company as a key player in the pharmaceutical industry.

Lucas

Series B in 2024
Lucas develops a system to detect, measure, categorize and track nodules in the screening CT images.

Superb AI

Series C in 2024
Superb AI is a training data platform that automates the preparation of data at scale, facilitating the rapid development and iteration of datasets for various applications. Founded in 2018 by a team of data scientists, academics, and machine learning engineers, the company aims to transform how organizations label, manage, and deliver training data. With extensive experience in computer vision and deep learning, Superb AI provides tools for data annotation, curation, model training, and deployment, streamlining the development of data-centric artificial intelligence projects. The platform is designed to enhance efficiency, allowing businesses to expedite the creation and deployment of computer vision applications.

Upstage

Series B in 2024
Upstage AI is a startup that specializes in providing customized artificial intelligence services to businesses. The company develops tailored AI models designed to address specific challenges faced by its clients, thereby enhancing operational efficiency and fostering innovation. By enabling organizations to focus on their core tasks, Upstage AI helps them leverage AI technology to solve problems and advance their business processes effectively.

AITRICS

Series B in 2024
AITRICS is a company focused on enhancing healthcare through its innovative clinical decision support platform. By leveraging machine learning technologies and evidence-based expert analysis, AITRICS aims to improve patient outcomes by providing real-time clinical insights. The platform transforms traditional reactive disease management into a proactive approach, emphasizing predictive, preventive, personalized, and participatory care. AITRICS brings together a diverse team of professionals dedicated to democratizing access to data-driven health intelligence, ultimately striving to revolutionize the way healthcare is delivered and experienced.

Bertis

Venture Round in 2024
Bertis Inc. is a proteomics-based molecular diagnostics company founded in 2014 and headquartered in Seongnam, South Korea. The company specializes in the development and commercialization of cancer-related biomarkers aimed at early disease detection. Its flagship product, Mastocheck, provides a screening method for diagnosing stage 1 breast cancer. Additionally, Bertis is engaged in research to create biomarkers for the early diagnosis of various carcinomas and to develop new therapeutic markers and co-markers. The company employs advanced bio-big data analysis technologies to discover and develop markers that integrate proteomics, genomics, and bioinformatics, enhancing the diagnostic capabilities for cancer and cardiac diseases.

Nventric

Series B in 2024
Nventric is a medical device company focused on developing innovative solutions for neurovascular, coronary heart, and peripheral vascular applications. The company specializes in creating devices aimed at addressing critical medical conditions, particularly those related to ischemic stroke. One of its key products is a stent retriever designed to be inserted into the artery in the leg, facilitating the removal of blood clots that lead to arterial occlusion. This technology enhances the ability of healthcare professionals to effectively treat ischemic stroke, ultimately improving patient outcomes. Nventric's commitment to advancing medical devices underscores its role in the healthcare sector, addressing significant challenges in vascular health.

Kanaph Therapeutics

Series C in 2023
Kanaph Therapeutics is a biotechnology company focused on developing next-generation therapeutics for oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company engages in drug development activities ranging from discovery to early-stage clinical trials. Its therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. In oncology, Kanaph Therapeutics develops drugs with enhanced immuno-stimulatory activity in the tumor microenvironment for efficient tumor eradication. For autoimmune diseases, the company's pipeline features bispecific Fc-fusions that inhibit the alternative complement pathway, angiogenesis, and downstream complement activation. The company serves both Korea and the United States.

Medipixel

Series B in 2023
Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Moloco

Series D in 2023
Moloco Inc., founded in 2013 and based in Palo Alto, California, specializes in programmatic advertising solutions aimed at optimizing client acquisition, retention, and monetization strategies. The company offers a cloud-based demand-side platform that leverages machine learning to help businesses of all sizes enhance user acquisition and maximize lifetime value through predictive models. Additionally, Moloco provides a mobile e-commerce platform that supports targeted re-engagement campaigns, allowing application publishers and e-commerce platforms to expand their customer reach more effectively than traditional advertising methods. With a team comprised of top talents from leading tech firms, Moloco is committed to empowering mobile businesses to thrive in a competitive landscape.

MangoBoost

Series A in 2023
MangoBoost is a technology company that specializes in advanced system solutions designed to enhance the efficiency of AI data centers. Central to its offerings is the MangoBoost DPU, which enables cost-effective, standards-based AI infrastructure by ensuring compatibility with all commodity GPUs, accelerators, and storage products. This innovation allows for the effective utilization of existing legacy infrastructure and simplifies network systems. Established in 2022, MangoBoost draws on a decade of prior research presented at leading conferences and comprises a team of over 80 professionals, including system architects, software engineers, and FPGA/SoC engineers, many of whom hold doctoral degrees from prestigious institutions and possess significant industry experience with major technology firms. The company has raised more than 60 million US dollars in funding and is actively expanding its operations in the United States, Canada, and South Korea.

EverEx

Series A in 2023
EverEx is a software-based therapeutics company specialized on musculoskeletal disorders with an AI-enabled pose estimation.

VCAT.AI

Series A in 2023
VCAT.AI is a business-to-business (B2B) subscription software (SaaS) based on AI technology. Create mass marketing creatives as video and banner images just with an product URL or TEXT.

Pion

Series A in 2023
Pion Corporation is a marketing technology company specializing in video intelligence. It offers "Vispot," an AI-driven platform for video creation and ad automation. This application is designed to assist video creatives by providing automated services for video production and optimization. By leveraging artificial intelligence, Pion enables businesses to enhance their marketing capabilities and streamline the video advertising process.

Ideahub

Venture Round in 2023
Ideahub Inc. is a professional services company specializing in patent monetization and intellectual property (IP) licensing. Founded in 2016 and headquartered in Seoul, South Korea, Ideahub offers a platform for the monetization of IP portfolios, along with licensing services and potential revenue analysis. The company's expertise spans various technology sectors, including the Internet of Things (IoT), industrial automation, telecommunications, audio technology, augmented reality (AR), virtual reality (VR), and video entertainment. Through its comprehensive services, Ideahub seeks to facilitate the effective commercialization of patents and intellectual property.

Toss Bank

Venture Round in 2023
Toss Bank is an internet banking services company based in South Korea, dedicated to financial innovation and inclusivity. As a challenger bank, it aims to reshape the traditional banking landscape by focusing on customer-centered solutions rather than a supplier-centric approach. Toss Bank provides a range of services tailored for both retail and commercial clients, including interest-bearing accounts, accessible deposit and withdrawal options, and straightforward loan processing. The bank also emphasizes serving economically disadvantaged individuals who have been excluded from conventional financial systems, thus striving to deliver essential financial services and improve overall access to banking.

Yipscell

Series B in 2022
Yipscell is a biotech company that develops IPSC stem cell therapy to diagnose and treat incurable diseases.

Onconic Therapeutics

Series B in 2022
Onconic Therapeutics is a biotechnology company dedicated to the research and development of innovative cancer treatments. The company focuses on creating next-generation anti-cancer therapies that target specific mechanisms involved in cancer progression. By simultaneously inhibiting signal delivery agents that promote cancer cell growth and DNA damage repair enzymes, Onconic Therapeutics aims to enhance the effectiveness of its therapies. This approach provides healthcare professionals with advanced options for treating various types of cancer, contributing to the ongoing efforts to improve patient outcomes in oncology.

LINE Studio

Private Equity Round in 2022
LINE Studio is a casual game developer associated with a global messaging platform. The company focuses on creating mobile games intended for the e-gaming sector, researching and developing titles across various genres. By prioritizing user engagement, LINE Studio aims to enhance leisure time for players, offering enjoyable and accessible gaming experiences.

EverEx

Funding Round in 2022
EverEx is a software-based therapeutics company specialized on musculoskeletal disorders with an AI-enabled pose estimation.

Codit

Seed Round in 2022
Codit is a company that has developed a data-monitoring platform focused on facilitating access to government information. Its platform allows clients to efficiently find, monitor, and analyze critical changes in local legislation, regulations, and policies that impact their businesses. By utilizing artificial intelligence, Codit aggregates data from various government and ministerial sources, providing users with a comprehensive and organized database that streamlines legal and regulatory research. The service includes features for tracking legislative bills, policies, and regulations, as well as engaging with government stakeholders. Codit also offers tools to synthesize lengthy documents into concise, digestible information. With a mission to assist policy managers, Codit aspires to expand its reach globally, aiming to become a primary hub for governmental information in regions such as South Korea, Singapore, and the United States. The platform has gained significant attention and a growing user base, underscoring its relevance in the field of legal and regulatory affairs.

Dudum

Seed Round in 2022
Dudum is a video production company that specializes in connecting brands with skilled video editors through its innovative platform. This platform not only allows businesses to find the right video-making professionals but also provides quotes tailored to their specific needs. Dudum offers a range of services, including graphics, product advertisements, and in-house training, empowering companies to create customized video campaigns suited to their requirements.

Superb AI

Series B in 2022
Superb AI is a training data platform that automates the preparation of data at scale, facilitating the rapid development and iteration of datasets for various applications. Founded in 2018 by a team of data scientists, academics, and machine learning engineers, the company aims to transform how organizations label, manage, and deliver training data. With extensive experience in computer vision and deep learning, Superb AI provides tools for data annotation, curation, model training, and deployment, streamlining the development of data-centric artificial intelligence projects. The platform is designed to enhance efficiency, allowing businesses to expedite the creation and deployment of computer vision applications.

SK Ecoplant

Venture Round in 2022
SK Ecoplant is a prominent global city developer and infrastructure builder, recognized as a leading subsidiary of SK Group. The company specializes in engineering projects on an EPCC (Engineering, Procurement, Construction, and Commissioning) basis, focusing on sectors such as refineries, petrochemicals, fertilizers, industrial plants, and environmental facilities. It has established a strong presence in the high-tech engineering market, with significant projects underway across various countries, including the U.S., Saudi Arabia, China, and more. SK Ecoplant is also committed to sustainability, integrating green practices into its operations to support economic growth and industrial development in Korea and beyond. By leveraging extensive project experience and advanced technology, the company aims to enhance its internal processes and expand its reach in overseas markets, positioning itself for future growth.

Boostimmune

Venture Round in 2022
Boostimmune is a biotech company focused on developing antibody-based therapies to address unmet needs in oncology by modulating the immune system. The company is dedicated to overcoming challenges in cancer treatment through innovative anti-cancer therapies that enhance the human immune response. Boostimmune specializes in the research and development of immuno-oncology drugs, including inhibitors targeting myeloid-derived suppressor cells (MDSCs), which play a role in suppressing immune action against cancer cells within the tumor microenvironment. By increasing the frequency and activity of T cells, Boostimmune aims to improve the effectiveness of cancer treatments and ultimately facilitate the destruction of cancer cells. The company is driven by a team of industry experts committed to advancing cancer therapy solutions.

Absology

Series B in 2022
Absology is a developer of in-vitro diagnostic systems focused on enhancing patient care and saving lives. The company offers a range of diagnostic kits, including those for testosterone, vitamin D, PSA, TSH, FreeT4, and PCT. In addition to these kits, Absology provides solutions for monitoring anti-cancer therapies, cardiovascular diseases, and Alzheimer's disease. By enabling doctors to accurately diagnose various medical conditions, Absology aims to facilitate appropriate and timely treatment for patients.

Xangle

Series B in 2022
Xangle is a comprehensive disclosure platform that specializes in collecting, verifying, and integrating corporate disclosures from global projects and companies involved in crypto assets. The company addresses the challenges of analyzing on-chain data by providing clear and accessible information, including both on-chain metrics and off-chain corporate disclosures. By consolidating and standardizing digital asset data, Xangle aims to enhance the public's understanding of crypto assets. Its platform serves as a resource for token projects, exchanges, and investors, facilitating the intrinsic valuation of projects and promoting best practices in public data disclosure. Through its user-friendly interface, Xangle strives to make vital information readily available, thereby contributing to the transparency and security of the digital asset ecosystem.

IVIM Technology

Series C in 2022
IVIM Technology, founded in 2017 and based in Daejeon, South Korea, specializes in developing and manufacturing advanced medical devices, particularly the IntraVital Microscopy platform. The company provides services such as live cell intravital imaging, repetitive intravital imaging, drug efficacy monitoring, delivery monitoring, and whole tissue 3D imaging. IVIM Technology's innovations focus on exploring cellular interactions within living organisms to understand complex human diseases better. Their technology is instrumental in analyzing the in vivo efficacy of new biopharmaceuticals, including immunological, cell, gene, and antibody therapeutic agents, at the cellular level.

M83

Venture Round in 2022
M83 is a specialized media studio that focuses on empowering film directors with advanced computer graphics and visual effects technologies to produce visually striking movies and television series.

Genecker

Venture Round in 2022
Genecker is a cancer diagnosis and testing center that specializes in genetic analysis services. The company offers a range of testing options, including cancer genome tests, prenatal genome assessments, rare disease evaluations, and individual genome analyses. Genecker's focus is on delivering personalized diagnosis, treatment, and healthcare methods, enhancing the quality of life for its clients. By providing advanced sequencing analysis and diagnostic technology, Genecker aims to empower individuals with accurate information regarding their health, facilitating informed decisions about their care.

KaliVir Immunotherapeutics

Series A in 2022
KaliVir Immunotherapeutics is a biopharmaceutical company focused on developing innovative oncolytic viral immunotherapy products aimed at treating various tumor types. Utilizing a next-generation vaccinia platform, KaliVir enhances systemic delivery capabilities, enabling targeted replication and spread of the virus within the tumor microenvironment. The company’s approach integrates technologies both developed in-house and licensed from the University of Pittsburgh, leveraging cutting-edge research in oncolytic viruses and immunotherapy. With a focus on tailored transgene programs, KaliVir offers healthcare professionals powerful tools designed to improve the effectiveness of cancer treatments through its proprietary genetic modifications.

Jobis

Venture Round in 2022
Jobis is an accounting management platform by AI.

Clodot

Series B in 2022
Clodot is an information technology company.

Law&Company

Series C in 2022
Law&Company is representative legal tech company in Republic of Korea. The company provides a service called 'LawTalk(www.lawtalk.co.kr)', which is the largest online legal market place in Korea(5 times bigger then the 2nd player). Since 2016, the company invested on research about Artificial Intelligence especially on Text Mining and Machine Learning technology to analyze lawyers and client's activities in the service which helps to lawyers and clients find the right person based on their experience. Also, the company will launch document automation based service to generate legal documents starting from complaint and contract soon. The company has received more than 3 million dollars from 5 venture capital companies and many angel investors due to previous performance and upside potential in the Korean legal market.

Immuneoncia Therapeutics

Secondary Market in 2022
ImmuneOncia Therapeutics Inc. is a biopharmaceutical company focused on developing anti-cancer therapies, specifically in the field of immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company is headquartered in Yongin-Si, South Korea. ImmuneOncia is dedicated to creating safe and effective immunotherapies for cancer patients worldwide, leveraging the expertise of its parent companies in drug development and antibody engineering. The company’s lead product, IMC-001, is a monoclonal antibody currently undergoing Phase 1 clinical trials, with a portfolio that includes various immune checkpoint antibodies aimed at treating multiple cancer types.

Lucas

Series A in 2021
Lucas develops a system to detect, measure, categorize and track nodules in the screening CT images.

Unlimeat

Venture Round in 2021
Unlimeat is a company specializing in the production of plant-based meat products designed to serve as sustainable and environmentally friendly food substitutes. Its product range includes sliced meats, minced meat, burger patties, and pulled barbecue, all crafted using technology that replicates the texture, juice, taste, and aroma of traditional meat. The company focuses on transforming perfectly edible but cosmetically imperfect produce that would otherwise go to waste into appealing plant-based foods, thereby promoting waste reduction. Unlimeat's offerings cater to a diverse culinary landscape, making them suitable for both Eastern and Western cuisines. Additionally, the company is a proud member of the Upcycled Food Association, underscoring its commitment to sustainability and responsible food production.

Breezytail

Series A in 2021
Breezytail is a pet service company that specializes in pet lifestyle products, with a strong emphasis on pet health care. The company offers a diverse range of products, including face care, hair care, and bath products, as well as various household goods. Through its offerings, Breezytail aims to enhance the well-being of pets, allowing them to live longer and healthier lives.

Upstage

Series A in 2021
Upstage AI is a startup that specializes in providing customized artificial intelligence services to businesses. The company develops tailored AI models designed to address specific challenges faced by its clients, thereby enhancing operational efficiency and fostering innovation. By enabling organizations to focus on their core tasks, Upstage AI helps them leverage AI technology to solve problems and advance their business processes effectively.

Munpia

Venture Round in 2021
Munpia Inc. is an online media company founded in 2012 and based in Seoul, South Korea. It specializes in publishing news and a comprehensive database focused on events and web novels. The company primarily caters to adult readers, with a significant emphasis on the martial arts genre. Munpia offers a platform that encourages the participation of both writers and readers, allowing emerging fantasy authors to share their stories and engage with an audience. Through its innovative approach, Munpia fosters a community for storytelling and genre exploration in the digital landscape.

Aardvark Therapeutics

Series B in 2021
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2017 by Tien Lee. The company focuses on developing and commercializing small molecule therapeutics specifically targeting obesity and rare genetic metabolic disorders. Its lead product, Bittera, is a first-in-class oral composition designed to selectively disrupt hunger signaling while regulating energy homeostasis, providing a novel treatment option that does not interfere with nutrient absorption. Through its innovative approach, Aardvark Therapeutics aims to offer effective and safe solutions for clinicians managing obesity-related diseases.

Karis Bio

Series A in 2021
Karis Bio is a biotechnology company focused on developing innovative cell therapies for cardiovascular diseases. It specializes in creating cell-based treatments that utilize patented technology for generating induced pluripotent stem cells (iPSCs) and differentiating them into endothelial cells. This advanced approach aims to enhance patient recovery from cardiovascular conditions, offering new possibilities for treatment in a field that requires effective solutions. By leveraging cutting-edge stem cell technology, Karis Bio is positioned to make significant contributions to the management and treatment of cardiovascular diseases.

April Bio

Series C in 2021
April Bio is a drug development company that develops antibodies and long-acting biologics.

Jeongyookgak

Series C in 2021
Jeongyookgak is a company that specializes in the production and sale of fresh meat and groceries. It offers a variety of food items, including pork, beef, eggs, and grass-fed meat, catering to customers seeking high-quality and healthy food options. The company emphasizes rapid delivery services, ensuring that customers receive their orders promptly. By providing online assistance for food delivery, Jeongyookgak aims to meet the growing demand for convenient access to fresh food at reasonable prices.

Publy

Series B in 2021
Publy is a content platform tailored for working individuals, focusing on providing subscription services for curated content. The platform allows users to create, design, archive, store, and publish custom content and events. By facilitating the purchase and reservation of content from various media sources, Publy empowers users to access and utilize both current and forthcoming materials. This innovative approach aims to enhance the way professionals engage with and manage content in their work environments.

Mega MGC Coffee

Venture Round in 2021
Mega MGC Coffee is a specialty store that offers a delightful range of beverages and robust coffee made from 100% Arabica beans. As the prices of coffee continue to rise, consumers are increasingly inclined towards low-cost coffee options. The escalating coffee prices have prompted people to actively seek out more affordable alternatives. Mega MGC Coffee, a budget-friendly coffee franchise, has garnered substantial attention in this context. As of January 5, 2023, the franchise had successfully established a cumulative total of 2,212 stores and consistently announced new store openings.

Reebonz Korea

Series A in 2021
Reebonz Korea, Ltd is a company based in Seoul, South Korea, specializing in the import, export, wholesale, and retail of luxury products for both men and women. The company provides a wide range of items, including bags, wallets, watches, shoes, clothing, cosmetics, and fashion accessories. Reebonz operates an e-commerce marketplace that features popular luxury goods as well as pre-owned items from coveted designer brands. The platform offers customers the convenience of shopping for the latest fashion items and includes options for both buying and selling, along with personalized services.

Barogo

Series C in 2021
Barogo provides a last-mile delivery platform to clients in order to generate new and creative business opportunities. It focuses on the ecosystem of connectivity and connects all possible businesses and customers. It was founded in 2014 and is based in Seoul, South Korea.

Hince

Series B in 2021
Hince is a cosmetics brand that specializes in a diverse range of personal care products, including skin, lip, eye, and face care items. The company focuses on developing mood narrative makeup products, which encompass lipsticks, compacts, eye shadows, and lip glosses. Hince emphasizes the use of natural and vegan ingredients in its offerings, catering to consumers who seek environmentally friendly and ethical options in their beauty routines. By providing a variety of high-quality cosmetics, Hince aims to enhance the beauty experience for its customers while promoting a commitment to sustainability.

Yipscell

Series A in 2021
Yipscell is a biotech company that develops IPSC stem cell therapy to diagnose and treat incurable diseases.

Iksuda Therapeutics

Series A in 2021
Iksuda Therapeutics is a biotechnology company focused on developing advanced biological therapies for treating challenging cancers, including those resistant to existing treatments. The company specializes in antibody-drug conjugates (ADCs), which combine monoclonal antibodies with potent cytotoxic drugs via a linker. By carefully selecting the right payload, linker, and conjugation chemistry, Iksuda aims to enhance cancer treatment efficacy while minimizing off-target toxicity.

Stars Tech

Venture Round in 2021
Traditional de-icers such as salt and calcium chloride are effective, but they also cause economic, health and environmental harms such as iron corrosion, concrete damage, plant sulfurization and respiratory problems. To solve this problem, STAR'S TECH developed and commercialized the world's first eco-friendly de-icing agent using starfish extract. This unique solution provides superior results when compared with other traditional de-icing methods. ECO-ST1 is an eco-friendly de-icing agent made from sea waste starfish. It is developed by researchers at Seoul National University and helps reduce the overhead costs of deicing by up to 90%. 80% of the cost of de-icing is overhead. ECO-ST1 prevents traffic accidents through rapid and continuous melting and minimizes iron corrosion and concrete damage to minimize the cost of repairing roads, bridges, vehicles, and guard rails. It also solves road damage by minimizing plant sulfurization. STAR'S TECH has developed an innovative technology to extract the porous structures from starfish. Unstable chloride ions resulting from deicing are absorbed by these porous structures through electrostatic force. Starfish extract helps control chloride ion concentration, which can otherwise be detrimental to the environment. This technology also enables corrosion inhibitor reaction by using very few anti-corrosion agents. ECO-ST1 is manufactured in a bead form rather than the commonly used flake form. This bead is coated with starfish extract and a diffuser for de-icing. Beads are advantageous because they have greater penetration and de-icing performance. Also, as this starfish-coated bead does not create dust, it does not cause respiratory problems.

Yunsung F&C

Venture Round in 2021
Yunsung F&C focus on the Engineering, Procurement, and Construction business. Yunsung F&C has played a significant role in the advancement of industries such as biopharmaceuticals, rechargeable batteries, and food. With its accumulated technology and expertise, Yunsung F&C focuses on EPC (Engineering, Procurement, and Construction) projects that encompass the entire process, from design and engineering to procurement, production, installation of equipment and materials, piping and electrical works, and the automatic control system. As a total solution partner, the company works hand in hand with its customers, utilizing its technical capabilities and know-how. Yunsung F&C is dedicated to contributing to the plant industry in Korea and expanding its reach as a global company, driven by its commitment to world-class quality and technology. The company also strives for sustainable quality innovation, customer satisfaction management, and the provision of superior products and services, aiming for mutual growth and prosperity alongside its valued customers.

Ably

Series B in 2021
Ably Corporation is a fashion platform that facilitates a marketplace where customers can sell products to one another. The platform features a forum that allows influencers and celebrities to create online stores, showcasing and selling products directly. This enables consumers to stay informed about the latest fashion trends and purchase clothing similar to that worn by their favorite public figures. Through its application, Ably aims to enhance the shopping experience by connecting users with trendy apparel and fostering a community around fashion.

Orum Therapeutics

Venture Round in 2021
Orum Therapeutics, Inc. is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of a novel class of therapeutic antibodies through its proprietary cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's approach enables the intracellular delivery of active antibody therapeutics or payloads, allowing it to inhibit drug targets that are typically considered undruggable by existing small molecules or antibody treatments. The technology is adaptable, capable of targeting various cell types and intracellular proteins without the need for chemical modifications. By merging the precision of antibodies with the efficacy of protein degraders, Orum aims to facilitate the development of new medicines that can effectively treat patients with challenging health conditions.

Mustbio

Venture Round in 2021
Mustbio is a biotechnology company founded in 2021 and based in Seoul, South Korea, specializing in the development of therapeutics for cancer treatment. The company utilizes a unique multi-antibody platform technology that mimics a natural-like asymmetric IgG form. This innovative approach facilitates a high rate of double antibody formation, enhancing the economic feasibility of its drug development. Mustbio focuses primarily on immuno-oncology, aiming to provide effective treatment options for patients facing various types of cancer.

Kmong

Series C in 2021
Kmong Inc. is a South Korean company that operates a freelance and micro-job marketplace, facilitating the exchange of services between individuals. Established in June 2012, the platform allows users to buy and sell a wide range of services across various categories, including design, IT and programming, marketing, consulting, translation, writing, and more. Freelancers can list their services with price quotes, making it easier for potential clients to find and engage with them. Kmong's services extend beyond traditional categories to include offerings like private lessons and unique personal services. The company is based in Seoul and provides a mobile application for Android devices, enhancing accessibility for users.

HOWSER

Series B in 2021
HOWSER provides furniture construction and delivery solutions through an online infrastructure based on IT technology.

Gbike

Series B in 2021
Gbike is a mobility sharing startup in Korea, innovating green urban mobility in Korea where currently car-centric environment. Our service includes bike and scooter sharing with IT services specialized for Korean market & Asia, Pacifics.

HealthHub

Venture Round in 2021
HealthHub is a healthcare company that specializes in developing cloud-based scientific image software aimed at enhancing medical interpretation. The platform integrates user interface and user experience design, developed in collaboration with radiologists, to create an optimized environment for individualized results. It facilitates real-time medical image exchange through a web-based suite, enabling hospitals to implement automatic remote solutions efficiently. This innovative approach aims to improve the accuracy and speed of medical imaging processes.

PlayList

Series B in 2021
PlayList is a web drama production company that specializes in creating and distributing dramas and music content through a digital platform. It has gained significant popularity among the 18-24 age demographic with its flagship web series, Love Playlist and A-Teen, which have collectively amassed over 10 million subscribers and 1.3 billion views. The company's focus on engaging and diverse content enables it to captivate a broad audience, particularly within the adult segment, while showcasing quality Korean shows across various genres.

House Decoration

Series B in 2021
House Decoration is a seller of home interiors, furniture, and home products.

Cookat

Venture Round in 2021
Cookat is a digital content creator specializing in food and culinary trends, focused on delivering engaging videos and unique recipes. The company operates a food blogging platform optimized for mobile users, allowing it to effectively share visually appealing food content across social media channels. By providing a space for food enthusiasts to explore innovative recipes and gourmet ideas, Cookat enhances consumer engagement and promotes the latest culinary trends. In addition to content creation, the platform facilitates the sale of wholesale items, including restaurant advertisements and home meal replacements, connecting consumers within the food market.

Onegene Biotechnology

Series A in 2021
Onegene Biotechnology is a biotechnology company focused on developing innovative protein-based drugs to treat cancer, metabolic, and inflammatory diseases. The company specializes in creating highly potent tri- or multispecific protein drugs by combining various molecular types, including Fab fragments, scFv, sdAb, peptides, cytokines, agonists/antagonists, and enzymes. This approach allows for an unprecedented level of design flexibility with optimized physical properties, opening new avenues for developing complex protein drugs that are feasible to manufacture. Onegene's technology involves protein conjugation, which connects two separate proteins to produce therapeutic recombinant proteins through post-translational fusion. This method enables the production of multi-target proteins with large molecular weights, providing prolonged holistic benefits for treating complex and multifactorial diseases.

Superb AI

Series A in 2021
Superb AI is a training data platform that automates the preparation of data at scale, facilitating the rapid development and iteration of datasets for various applications. Founded in 2018 by a team of data scientists, academics, and machine learning engineers, the company aims to transform how organizations label, manage, and deliver training data. With extensive experience in computer vision and deep learning, Superb AI provides tools for data annotation, curation, model training, and deployment, streamlining the development of data-centric artificial intelligence projects. The platform is designed to enhance efficiency, allowing businesses to expedite the creation and deployment of computer vision applications.

Jobis

Venture Round in 2021
Jobis is an accounting management platform by AI.

Bertis

Venture Round in 2020
Bertis Inc. is a proteomics-based molecular diagnostics company founded in 2014 and headquartered in Seongnam, South Korea. The company specializes in the development and commercialization of cancer-related biomarkers aimed at early disease detection. Its flagship product, Mastocheck, provides a screening method for diagnosing stage 1 breast cancer. Additionally, Bertis is engaged in research to create biomarkers for the early diagnosis of various carcinomas and to develop new therapeutic markers and co-markers. The company employs advanced bio-big data analysis technologies to discover and develop markers that integrate proteomics, genomics, and bioinformatics, enhancing the diagnostic capabilities for cancer and cardiac diseases.

LUNASOFT

Series B in 2020
LUNASOFT INC. is a South Korean company founded in 2016, specializing in the development of chatbots and integrated management platforms aimed at enhancing customer support. The company offers a range of solutions, including Luna Plus, a courier exchange platform; Luna Plus Mobile, which facilitates real-time business consultations; and Luna Plus CTI, a customer counseling platform that combines phone and intelligent chat counseling. Additionally, LUNASOFT develops customer consultation chatbots tailored for popular messaging platforms such as Naver and Kakao, primarily catering to e-commerce businesses. Based in Seoul, LUNASOFT is focused on providing innovative chat solutions to improve customer interaction and support processes.

Chatie

Venture Round in 2020
Chatie is a technology company specializing in the development of a unique story-writing application. This platform allows users to create and share stories in various formats, including romantic, horror, and fanfiction genres. The application supports multiple media types such as text, video, photos, and sound, along with optional endings, making it accessible and engaging for both writers and readers.

Vastera

Venture Round in 2020
Bastera is a biotech company with the primary goal of developing groundbreaking treatments for cardiovascular and cancer diseases. Their approach involves targeting new redox signaling pathways, aiming to pioneer "first-in-class" therapies in these fields. Vastera was established in 2018 when SangWon Kang, a professor at Ewha Womans University, transferred a patent based on research results on redox signaling in blood vessels and cancer.

3ProTV

Venture Round in 2020
3ProTV leads the way in disseminating financial knowledge with valuable and comprehensive economic and financial content, playing a prominent role in the industry. 3ProTV is an economic radio station that provides a distinctive depth of content. For those who find the economy perplexing due to numbers and graphs, they strive to simplify and clarify economic concepts using captivating stories and relatable analogies.

Fitpet

Series B in 2020
Fitpet is a developer of a veterinary application focused on enhancing the quality of life for companion animals and their caregivers through technological innovation. The application provides real-time insights into a pet's health status by conducting a comprehensive analysis of various parameters, allowing pet owners to better understand and manage their pets' well-being. Committed to fostering a sustainable and pet-friendly society, Fitpet aims to leverage information technology to improve the overall care experience for both pets and their human companions.

SK Innovation

Venture Round in 2020
SK Innovation Co., Ltd. is a global energy and chemical company headquartered in Seoul, South Korea. Established in 1962, it operates through four main segments: Petroleum, Petrochemicals, Lubricants, and Others. The company is involved in the exploration, development, and production of crude oil and natural gas, with operations in countries such as the United States, Peru, Vietnam, and China. SK Innovation refines petroleum products, including gasoline, diesel, and aviation fuel, which it supplies to distributors, gas stations, and consumers. Additionally, the company produces a wide range of petrochemical products, such as olefins, synthetic resins, and lubricants, as well as high-capacity lithium-ion batteries for electric vehicles. Beyond its core operations, SK Innovation also provides various services, including insurance and business consulting, and operates a professional football club. With a commitment to innovation, the company has expanded its footprint in both traditional and future energy sectors.

Saige Research

Series A in 2020
Saige Research is a company that specializes in developing artificial intelligence solutions tailored for industrial inspection and quality control within the manufacturing sector. It offers a deep learning vision inspection platform designed to address the challenges faced by inspectors, enhancing operational efficiency. The technology features capabilities such as power detection, speed detection, and versatility, allowing for seamless integration and development. By automating the inspection process, Saige Research aims to provide optimal AI solutions that improve product quality and streamline workflows in manufacturing environments.

Jeongyookgak

Series B in 2020
Jeongyookgak is a company that specializes in the production and sale of fresh meat and groceries. It offers a variety of food items, including pork, beef, eggs, and grass-fed meat, catering to customers seeking high-quality and healthy food options. The company emphasizes rapid delivery services, ensuring that customers receive their orders promptly. By providing online assistance for food delivery, Jeongyookgak aims to meet the growing demand for convenient access to fresh food at reasonable prices.

Toss Payments

Venture Round in 2020
Toss Payments is a technology company that develops an electronic payment management platform. This platform simplifies transaction processes by offering features such as account transfers, virtual accounts, easy payment methods, mobile micropayments, billing tools, gift voucher payments, and automatic transfer services. It caters to startups, businesses, and public institutions, enabling them to transfer money efficiently, reduce settlement cycles, and maintain smooth cash flow.

Ubix Therapeutics

Series B in 2020
Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

Noul

Venture Round in 2020
Noul is a healthcare technology company that develops innovative diagnostic solutions to tackle chronic and systemic health issues globally. Its flagship product, miLab, is an automated device that combines sample preparation and artificial intelligence-based diagnostics into a single workflow, integrating computer vision AI, biotechnology, hardware, and software engineering. Noul aims to enhance human health by contributing to the eradication of infectious and non-infectious diseases.

Healing Paper

Series B in 2020
Healing Paper is a company focused on enhancing access to medical beauty services through the use of information and communication technology. It operates a platform that provides estimates and reviews for cosmetic surgeries, aimed at improving the quality of these services. The platform offers users transparent pricing information, authentic reviews, and a community for real-time interaction regarding cosmetic procedures. Additionally, Healing Paper includes a management package for aftercare, ensuring that patients receive comprehensive support throughout their treatment journey. By balancing information between medical professionals and patients, the company strives to make cosmetic treatments more accessible and affordable.

Musicow

Series B in 2020
Musicow, Inc. is a company based in Seoul, South Korea, that operates an online platform facilitating the investment in music copyrights. Founded in 2017, Musicow allows musical artists to share their copyright with fans, enabling fans to invest in K-Pop songs through a public auction or an online marketplace. The platform offers users the ability to buy and sell fractional ownership of music rights, thereby creating opportunities for fans and investors to earn royalties based on the streaming and usage of the songs. Additionally, Musicow features a secondary marketplace for music copyright trading and project financing, enhancing participation in the music industry and allowing for potential returns on investments.

StyleShare

Series D in 2020
StyleShare Inc. is a South Korean company founded in 2011 that specializes in designing and developing a mobile and web application focused on fashion, beauty, and lifestyle. The platform serves as a real-time space for users to share and receive updates related to these interests, allowing individuals to showcase their daily outfits and recent purchases. With millions of users across 120 countries, StyleShare has established itself as a leading mobile platform in the fashion and beauty sector, earning recognition from prominent publications such as VOGUE, Instyle, and Elle Japan. Through its innovative application, StyleShare facilitates a vibrant community where users can connect over their shared passion for fashion.

AITRICS

Series A in 2020
AITRICS is a company focused on enhancing healthcare through its innovative clinical decision support platform. By leveraging machine learning technologies and evidence-based expert analysis, AITRICS aims to improve patient outcomes by providing real-time clinical insights. The platform transforms traditional reactive disease management into a proactive approach, emphasizing predictive, preventive, personalized, and participatory care. AITRICS brings together a diverse team of professionals dedicated to democratizing access to data-driven health intelligence, ultimately striving to revolutionize the way healthcare is delivered and experienced.

StyleShare

Venture Round in 2020
StyleShare Inc. is a South Korean company founded in 2011 that specializes in designing and developing a mobile and web application focused on fashion, beauty, and lifestyle. The platform serves as a real-time space for users to share and receive updates related to these interests, allowing individuals to showcase their daily outfits and recent purchases. With millions of users across 120 countries, StyleShare has established itself as a leading mobile platform in the fashion and beauty sector, earning recognition from prominent publications such as VOGUE, Instyle, and Elle Japan. Through its innovative application, StyleShare facilitates a vibrant community where users can connect over their shared passion for fashion.

OnePredict

Series B in 2019
OnePredict, established in 2016, is a prominent player in the field of industrial AI technology, recognized for its innovative solutions and a record nine wins at the Global PHM Data Challenge. The company specializes in the development of the GuardiOne® Series, which offers advanced AI solutions tailored for various industrial applications, including bearings, turbines, wind farms, transformers, robots, and motors. OnePredict's machine intelligence software is designed to transform data into actionable industrial intelligence, providing predictive analytics that help businesses assess the risk of equipment failure and determine the remaining lifecycle of critical assets. By optimizing hardware for real-time processing, OnePredict enables companies to make informed and timely decisions, thereby enhancing operational efficiency across diverse industries.

Supergene

Series B in 2019
Supergene is a social content and HTML5 game development company located in Pangyo, South Korea, and Manila, Philippines. The company specializes in creating instant mobile games and social content, having launched over 30 games on the Facebook Gaming platform. Among its notable titles are Signal, The Puzzle, OMG, OMG AR, Puzzle Wizard, and Super Pop. Supergene's game OMG achieved significant popularity, reaching the top position in monthly active users in 2020, with 300 million users at its peak. By enabling users to play games and share their results on social media, Supergene aims to enhance social interaction among gamers while providing engaging entertainment options.

GF Fermentec

Venture Round in 2019
GF Fermentec is a biotechnology company specializing in the production of bioactive biomaterials, specifically designed for use in cosmetic applications. The company focuses on developing core raw materials, such as ceramides, which are essential for skin moisturizing and the improvement of atopic conditions. Utilizing advanced fermentation technology, GF Fermentec supplies cosmetic firms with safe and effective raw materials, contributing to the creation of high-quality skincare products. Through its innovative approach, the company aims to enhance the efficacy and safety of cosmetic formulations.

DCGen

Venture Round in 2019
DCGen is a biotechnology company that specializes in the development of a multigene assay kit aimed at improving breast cancer prognosis. The company's innovative kit analyzes breast cancer-specific somatic mutation genes, facilitating the selection of effective treatment options for patients. By leveraging genomic analysis technologies, DCGen aims to enhance the decision-making capabilities of physicians, ultimately empowering doctors, patients, and their families in the context of cancer treatment and research. Through its advanced offerings, DCGen seeks to contribute significantly to the field of breast cancer management and improve clinical outcomes.

Aardvark Therapeutics

Series A in 2019
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2017 by Tien Lee. The company focuses on developing and commercializing small molecule therapeutics specifically targeting obesity and rare genetic metabolic disorders. Its lead product, Bittera, is a first-in-class oral composition designed to selectively disrupt hunger signaling while regulating energy homeostasis, providing a novel treatment option that does not interfere with nutrient absorption. Through its innovative approach, Aardvark Therapeutics aims to offer effective and safe solutions for clinicians managing obesity-related diseases.

MUSINSA

Venture Round in 2019
Musinsa Co., Ltd. is a fashion-focused company based in Seoul, South Korea, established in 2012. It operates both online and offline, offering a diverse range of products that include apparel, footwear, accessories, cosmetics, and more. Musinsa serves as a platform for various brands, including subculture, national, and global sports brands, providing customers with curated content, styling pictorials, and information on fashion trends. The company emphasizes customer engagement by allowing users to interact with brands and access personalized curation and storytelling. Additionally, Musinsa publishes an online fashion web magazine that showcases product information and brand highlights, further enriching the fashion culture and consumption experience in the Korean market.

Woollim Entertainment

Venture Round in 2019
Woollim Entertainment is an entertainment company focused on managing global cultural content and event services. The company aims to redefine the global cultural content industry by leveraging its extensive expertise and communication strategies developed through diverse projects. Woollim Entertainment is dedicated to discovering and nurturing artists capable of succeeding in the international market while facilitating various entertainment ventures. Through its systematic approach, the company enables clients to successfully produce and promote a wide array of artists, contributing to the vibrant landscape of global entertainment.

Law&Company

Series B in 2019
Law&Company is representative legal tech company in Republic of Korea. The company provides a service called 'LawTalk(www.lawtalk.co.kr)', which is the largest online legal market place in Korea(5 times bigger then the 2nd player). Since 2016, the company invested on research about Artificial Intelligence especially on Text Mining and Machine Learning technology to analyze lawyers and client's activities in the service which helps to lawyers and clients find the right person based on their experience. Also, the company will launch document automation based service to generate legal documents starting from complaint and contract soon. The company has received more than 3 million dollars from 5 venture capital companies and many angel investors due to previous performance and upside potential in the Korean legal market.

Fast Five

Series D in 2019
Fast Five is a premium SOHO office business center designed to provide attractive and efficient co-working spaces for startups and small-to-medium-sized companies. The company operates a membership-based model that allows members to access office spaces in high-demand locations without requiring a deposit. Fast Five aims to foster a sense of community among its members, facilitated by a community manager who helps build connections among founders, investors, professionals, and freelancers. The office environment is enhanced by communal perks such as free coffee, draft beer, and networking events, which promote collaboration and social interaction among members.

Riiid

Series C in 2019
Riiid is a global innovator in AI-powered education solutions, specializing in adaptive assessment platforms that personalize learning experiences for students worldwide. Launched in 2017 with Santa TOEIC, its flagship product has reached over one million users in Korea alone, demonstrating proven efficacy. Expanding globally, Riiid operates Santa TOEIC in Japan and offers Santa SAT in Vietnam. Its scalable AI technology provides each student with a personalized tutor, enhancing learning outcomes while reducing costs compared to traditional methods. By democratizing educational opportunities, Riiid is rapidly transforming the learning landscape.

Blackthorn Therapeutics

Series B in 2019
Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Zamong

Series A in 2019
Zamong is a multi-channel network company that caters to one-person media content creators by offering a range of services designed to simplify content creation. The company focuses on providing creator education, which is primarily developed and operated in collaboration with public institutions and businesses. Zamong also offers access to shared studios, creator portal services, and creator management solutions, which facilitate the production and distribution of personal or corporate broadcasting content. Through these offerings, Zamong enables its clients to create and manage their media content efficiently, positioning itself as a valuable partner for individual creators in the media landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.